News & Updates
Filter by Specialty:
Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD
Olaparib demonstrates clinical activity across patients with platinum-sensitive relapsed ovarian cancer and known BRCA mutation and homologous recombination deficiency (HRD), as shown in the phase II LIGHT study.
Olaparib safe, effective in ovarian cancer patients with BRCA mutation, HRD
15 Jul 2022
Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.
Trastuzumab deruxtecan for HER2-low breast cancer: A treatment for a new population
14 Jul 2022
Upadacitinib works in select ankylosing spondylitis patients
The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.
Upadacitinib works in select ankylosing spondylitis patients
14 Jul 2022
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
13 Jul 2022
Dextromethorphan-bupropion relieves symptoms in major depressive disorder
Treatment with dextromethorphan-bupropion (AXS-05) significantly improves depressive symptoms relative to bupropion alone and is well tolerated in patients with major depression, results of a phase II trial have shown.
Dextromethorphan-bupropion relieves symptoms in major depressive disorder
13 Jul 2022
Ozoralizumab shows therapeutic potential in rheumatoid arthritis
Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.
